

Pharmacy Pearls for Prescribers- Diabetes Part 2

Enduring Material

**** An e-learning course available on the Avera portal ****

Program Goal

Pharmacy Pearls for Prescribers provides up-to-date information on medications, developed by a multidisciplinary group of AMG primary care physicians and pharmacists from Avera Health and Avera Health Insurance Division. An interdisciplinary group has been working to develop educational materials to meet this need. In this series we will discuss diabetes management related to: sodium-glucose co-transporter 2 (SGLT2) inhibitors in the management of chronic kidney disease, GLP-1 receptor agonists are not all created equal, methods and monitoring for diabetes, and clinical utilization of continuous glucose monitoring (CGM).

Objectives

- 1 Review sodium-glucose co-transporter 2 (SGLT2) inhibitors in the management of chronic kidney disease
- 2 Discuss GLP-1 receptor agonists (GLP-1 RA) and how they are not all created equal
- 3 Identify methods of monitoring for diabetes
- 4 Describe the clinical utilization of continuous glucose monitoring (CGM)

Outcome

100% of participants will demonstrate their knowledge of diabetes management by passing a post test with a score of 80% or better.

Target Audience

Professions – Physician, Pharmacist, Nurse - Nurse Practitioner, Physician Assistant, Nurse -LPN/LVN

Specialties – Other

Completion Requirements

- Read entire document
- Complete the post-test
- Complete the evaluation

Accreditation & Credit Designation

Physicians

Avera is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Avera designates this educational activity for a maximum of **1.00 AMA PRA Category 1 Credits(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (NCPD)

Avera is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. A total of **1.00** contact hours can be received upon completion of this education activity. Attendance at the entire educational activity is required to receive contact hours. This activity has been approved for 1.0 pharmacotherapeutic credits.

Additional Information

Feedback person for this educational activity is: averacontinuingeducation@avera.org

Enduring material available from 1/25/2022 to 12/31/2022

This course content was reviewed on 1/12/2022

Disclosure Policy

Due to the regulations required for CE credits all conflict of interest that persons in a position to control or influence the education must be fully disclosed to participants. In observance of this requirement we are providing the following disclosure information: all relevant financial relationships disclosed below have been mitigated.

Name of individual	Individual's role in activity	Name of commercial interest/Nature of relationship
Thomas J Babb, PharmD	Committee Planning Member	Nothing to disclose
Allison 4472 Hein 4972, PharmD	Committee Planning Member	Nothing to disclose
Luke Merkel, PharmD	Committee Planning Member	Nothing to disclose
Lena Tran, MA, Adult Education	Committee Planning Member	Nothing to disclose
Rebecca VandeKop, MD	Content Expert - Committee Member	Nothing to disclose
Rachelle Davis-R-6716, PharmD	Content Expert - Committee Member, Faculty	Nothing to disclose
Drew L Klinkebiel - 6251, PharmD	Faculty	Nothing to disclose
April Krull, PharmD	Faculty	Nothing to disclose
Chad Thury, DO	Lead Planner	Nothing to disclose
Amy Skoglund, RN, Nurse	Nurse Planner	Nothing to disclose

